Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma.

ABSTRACT:

Purpose

To evaluate the impact of treatment for Hodgkin lymphoma (HL) on clinical reproductive markers and pregnancy outcomes.

Methods

This study was embedded within the DCOG LATER-VEVO study; a Dutch, multicenter, retrospective cohort study between 2004 and 2014. Serum anti-Müllerian hormone (AMH), follicle stimulating hormone (FSH), inhibin B, antral follicle count (AFC), and self-reported (first) pregnancy outcomes were evaluated in female childhood HL survivors and controls.

Results

84 HL survivors and 798 controls were included, aged 29.6 and 32.7 years old at time of assessment. Median age at HL diagnosis was 13.4 years. Cyclophosphamide equivalent dose (CED-score) exceeded 6000 mg/m² in 56 women and 14 survivors received pelvic irradiation. All clini

SUBMITTER: Drechsel KCE 

PROVIDER: S-EPMC10590326 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature